<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038127</url>
  </required_header>
  <id_info>
    <org_study_id>GangwonPCI</org_study_id>
    <nct_id>NCT02038127</nct_id>
  </id_info>
  <brief_title>Gangwon PCI Registry</brief_title>
  <acronym>GWPCI</acronym>
  <official_title>Prospective Registry for Patients Undergoing Coronary Angiography and Percutaneous Coronary Intervention in Gangwon Province</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gangwon Cardiovascular Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of

        -  Biolimus-eluting stent, Biomatrix, or Biomatrix Flex stent, Biosensors, Singapore

        -  Everolimus-eluting stent, Xience V, or Xience Prime, or Xience Xpedition stent, Abbott,
           USA

        -  Zotarolimus-eluting stent, Endeavor Resolute, or Endeavor Resolute Integrity stent
           Medtronic, USA in patients with coronary artery disease treated with percutaneous
           coronary intervention
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Device-oriented composite outcome</measure>
    <time_frame>24 months</time_frame>
    <description>Device-oriented composite consisted of cardiac death, MI not clearly attributable to a nontarget vessel, and clinically indicated TLR at 24-month clinical follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite outcome</measure>
    <time_frame>24 months</time_frame>
    <description>Patient-oriented composite consisted of all-cause mortality, any MI, and any revascularization at 24-month clinical follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARC defined stent thrombosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARC defined stent thrombosis</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      CBC, Electrolyte, Chemistry, Cardiac biomarker, Platelet function test
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were at least 18 years of age, who have stable coronary artery disease (CAD)
        or acute coronary syndrome (ACS), including myocardial infarction (MI) with or without
        ST-segment elevation will be included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 19 years

          -  Subject is able to verbally confirm understanding of risks, benefits and treatment
             alternatives of receiving the drug-eluting stent(s) and he/she or his/her legally
             authorized representative provides written informed consent prior to any study related
             procedure

          -  Subject must have significant stenosis (&gt;50% by visual estimate) on a native or
             in-stent coronary artery

          -  Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina,
             recent infarction, acute myocardial infarction, positive functional study or a
             reversible changes in the ECG consistent with ischemia). In subjects with coronary
             artery stenosis &gt;75%, evidence of myocardial ischemia does not have to be documented

        Exclusion Criteria:

          -  Subject has a known hypersensitivity or contraindication to any of the following
             medications: heparin, aspirin, clopidogrel, prasugrel, ticagrelor, biolimus A9,
             everolimus, zotarolimus, stainless steel, cobalt chromium, contrast media (Patients
             with documented sensitivity to contrast media, which can be effectively premedicated
             with steroid and diphenhydramine may be enrolled. However, those with true anaphylaxis
             to prior contrast media should not be enrolled.)

          -  Subject in use of systemic (intravenous) biolimus A9, everolimus or zotarolimus within
             12 months.

          -  Female subject of childbearing potential, unless a recent pregnancy test is negative,
             who possibly plans to become pregnant any time after enrollment into this study

          -  Subject planned an elective surgical procedure that would necessitate interruption of
             antiplatelet during the first 12 months post enrollment

          -  Subject with non-cardiac co-morbid condition with life expectancy &lt; 2 year or that may
             result in protocol non-compliance (per site investigator's medical judgment)

          -  Subject with cardiogenic shock at presentation

          -  Subject who are actively participating in another drug or device investigational
             study, who have not completed the primary end point follow-up period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junghan Yoon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junghan Yoon, M.D., Ph.D.</last_name>
    <phone>+82-33-741-0906</phone>
    <email>jyoon@yonsei.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young Jin Youn, M.D.</last_name>
    <phone>+82-33-741-0917</phone>
    <email>younyj@yonsei.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chuncheon Hallym University Hospital</name>
      <address>
        <city>Chuncheon</city>
        <state>Gangwon</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyun Hee Choi, M.D.</last_name>
      <email>jumdure@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Hyun Hee Choi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon</state>
        <zip>220768</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junghan Yoon, M.D., Ph.D.</last_name>
      <phone>+82-33-741-0906</phone>
      <email>jyoon@yonsei.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Young Jin Youn, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Junghan Yoon, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seung-Hwan Lee, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sung-Gyun Ahn, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun-Won Lee, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheol Ung Choi, M.D., Ph.D.</last_name>
      <email>wmagpie@korea.com</email>
    </contact>
    <investigator>
      <last_name>Cheol Ung Choi, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2014</study_first_posted>
  <last_update_submitted>November 14, 2016</last_update_submitted>
  <last_update_submitted_qc>November 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Yoon Junghan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

